Evidence map›Paper›PMID 31405374›Full record

ArticleMicrobial cell factories2019

Metabolic engineering of Bacillus megaterium for heparosan biosynthesis using Pasteurella multocida heparosan synthase, PmHS2.

Asher Williams, Kamil S Gedeon, Deepika Vaidyanathan, Yanlei Yu, Cynthia H Collins, Jonathan S Dordick, Robert J Linhardt, Mattheos A G Koffas

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 46 citations in OpenAlex.

  1. Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026
    Review
  2. Article
  3. Article
  4. PHB production by Bacillus megaterium strain MNSH1-9K-1 using low-cost media.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  5. Review
  6. Article
  7. Bioengineered production of glycosaminoglycans and their analogues.Systems microbiology and biomanufacturing · 2021
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Asher WilliamsDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Kamil S GedeonDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Deepika VaidyanathanDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Yanlei YuCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.
Cynthia H CollinsDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Jonathan S DordickDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Robert J LinhardtDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Mattheos A G KoffasDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA. koffam@rpi.edu.
Rensselaer Polytechnic Institute · US

Funding

National Science Foundation CBET-1604547
6 · The paper itself

Abstract

backgroundHeparosan is the unsulfated precursor of heparin and heparan sulfate and its synthesis is typically the first step in the production of bioengineered heparin. In addition to its utility as the starting material for this important anticoagulant and anti-inflammatory drug, heparosan is a versatile compound that possesses suitable chemical and physical properties for making a variety of high-quality tissue engineering biomaterials, gels and scaffolds, as well as serving as a drug delivery vehicle. The selected production host was the Gram-positive bacterium Bacillus megaterium, which represents an increasingly used choice for high-yield production of intra- and extracellular biomolecules for scientific and industrial applications.

resultsWe have engineered the metabolism of B. megaterium to produce heparosan, using a T7 RNA polymerase (T7 RNAP) expression system. This system, which allows tightly regulated and efficient induction of genes of interest, has been co-opted for control of Pasteurella multocida heparosan synthase (PmHS2). Specifically, we show that B. megaterium MS941 cells co-transformed with pT7-RNAP and pPT7_PmHS2 plasmids are capable of producing heparosan upon induction with xylose, providing an alternate, safe source of heparosan. Productivities of ~ 250 mg/L of heparosan in shake flasks and ~ 2.74 g/L in fed-batch cultivation were reached. The polydisperse Pasteurella heparosan synthase products from B. megaterium primarily consisted of a relatively high molecular weight (MW) heparosan (~ 200-300 kD) that may be appropriate for producing certain biomaterials; while the less abundant lower MW heparosan fractions (~ 10-40 kD) can be a suitable starting material for heparin synthesis.

conclusionWe have successfully engineered an asporogenic and non-pathogenic B. megaterium host strain to produce heparosan for various applications, through a combination of genetic manipulation and growth optimization strategies. The heparosan products from B. megaterium display a different range of MW products than traditional E. coli K5 products, diversifying its potential applications and facilitating increased product utility.

Indexed as

Bacillus megateriumBacterial ProteinsBiosynthetic PathwaysDisaccharidesDNA-Directed RNA PolymerasesGenetic EngineeringGlycosyltransferasesMetabolic EngineeringPasteurella multocidaViral ProteinsBacterial Proteinsbacteriophage T7 RNA polymeraseDisaccharidesDNA-Directed RNA PolymerasesGlycosyltransferasesheparosanheparosan synthaseViral ProteinsBacillus megateriumGlycosaminoglycansHeparosanHeparosan synthaseMetabolic engineering

Identifiers

PMID31405374
PMCPMC6691538
OpenAlexW2967102516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.